A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Funding: this study was funded by Sanofi. Acknowledgments: the authors thank the participating patients and their caregivers, the study centers, and the study investigators for their contributions to the study. The authors also thank Honghong Dong, MS, of Sanofi Research & Development, Bridgewat...

Descripción completa

Detalles Bibliográficos
Autores: Quach, Hang, Parmar, Gurdeep, Ocio San Miguel, Enrique María|||0000-0002-5765-0085, Prince, H. Miles, Oriol, Albert, Crowther, Helen, Tsukada, Nobuhiro, Bories, Pierre, Madan, Sumit, Nathwani, Nitya, Sunami, Kazutaka, Semiond, Dorothee, Yu, Disa, Cordero, Paul, Macé, Sandrine, Suzan, Florence, Moreau, Philippe
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/34533
Acceso en línea:https://hdl.handle.net/10902/34533
Access Level:acceso abierto
Descripción
Sumario:Funding: this study was funded by Sanofi. Acknowledgments: the authors thank the participating patients and their caregivers, the study centers, and the study investigators for their contributions to the study. The authors also thank Honghong Dong, MS, of Sanofi Research & Development, Bridgewater NJ, USA, for her contribution to the statistical analyses for this study, and BioCytex (a Stago Group company) for their contribution to the immunophenotyping analyses. The on-body delivery system was manufactured by Enable Injections, Inc. Medical writing support was provided by S. Mariani, MD, PhD of Envision Pharma Group, funded by Sanofi.

Similares en LA Referencia